Inspire Medical Systems heads into its Q2 earnings report tonight carrying a heavily shorted float, a cautious options market, and a Street that has turned meaningfully more bearish since the last disastrous print.
The options market is the clearest signal of investor anxiety. The put/call ratio has climbed to 1.46, well above its 20-day average of 1.04 — a reading that places defensive positioning about 1.15 standard deviations above normal ahead of the release. That skew matters in context: the last time INSP reported, the stock fell nearly 15% in a single session and lost more than 23% over the following five days, after the company slashed full-year revenue guidance to $950–$1,000 million from the prior $1,003–$1,013 million range. Options traders appear to be pricing in the possibility of a repeat.
Short interest adds weight to the bearish lean. At 14.3% of the free float — roughly 4.1 million shares — INSP is among the more heavily shorted names in the medtech universe. The short position grew about 3% over the past week and is up more than 14% over the past month, a sustained build that signals conviction rather than noise. The borrow market, however, is not tight. Availability is running near 770% — meaning roughly seven shares remain available to borrow for every one already lent out — and borrowing costs are negligible at just 0.51%. That combination of high short interest and ample availability suggests short sellers face no mechanical squeeze pressure heading into the print.
The analyst debate is lopsided. UBS assumed coverage just last week with a Sell rating and a $39 target — well below the current $52.22 price — while simultaneously cutting from the prior $67 target. Evercore downgraded to In-Line in late June, citing reimbursement headwinds. The two most constructive recent voices are Truist, which raised its Hold target modestly to $54, and Freedom Capital, which initiated at Buy with a $62 target in early July. The consensus mean target of $51.79 barely clears the current price, indicating the Street sees almost no upside on average. Bears point to the reimbursement and coding uncertainty that is decelerating domestic procedural volumes and argue that a lower valuation multiple is warranted. Bulls counter that aggressive marketing investment, growing headcount, and expected double-digit global HGNS market growth could support a recovery in 2026 — but the guidance cut has made that case harder to sustain.
One institutional wrinkle worth noting: BlackRock added 755,000 shares in Q2, lifting its stake to 14.4% of shares outstanding. Wellington and D.E. Shaw also added meaningfully. That institutional accumulation at depressed levels introduces a stabilising buyer base — but it has not stopped shorts from pressing their position higher.
Tonight's print is less about whether INSP is a structurally broken business and more about whether management can deliver any sign that reimbursement headwinds are stabilising and that domestic growth can reaccelerate — or whether the guidance corridor of $950–$1,000 million faces further compression.
See the live data behind this article on ORTEX.
Open INSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
